SCHEMBL12201465

SCHEMBL12201465

COc1ccc(NS(=O)(=O)c2ccc(C)cc2)c(C(=O)Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.60
FFAR4 Q5NUL3 3/20 0.60
CYP1A2 P05177 1/20 0.60
KCNA5 P22460 1/20 0.60
LMNA P02545 5/20 0.58
MAPT P10636 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
KMT2A Q03164 2/20 0.58
MEN1 O00255 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
ALDH1A1 P00352 3/20 0.55
GAA P10253 2/20 0.55
KDM4E B2RXH2 1/20 0.55
METAP2 P50579 2/20 0.53
HTT P42858 2/20 0.52
TP53 P04637 1/20 0.52
HPGD P15428 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
TSHR P16473 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31138312 0.88 FFAR4 (0.65) CYP2C9FFAR4CYP1A2KCNA5LMNA
SCHEMBL12200967 0.88 CYP2C9 (0.76) CYP2C9FFAR4CYP1A2KCNA5LMNA
SCHEMBL23200363 0.88 FFAR4 (0.65) CYP2C9FFAR4CYP1A2KCNA5LMNA
SCHEMBL29834293 0.84 LMNA (0.63) CYP2C9FFAR4CYP1A2KCNA5LMNA
SCHEMBL23200281 0.84 LMNA (0.63) CYP2C9FFAR4CYP1A2KCNA5LMNA
SCHEMBL28995980 0.84 KCNA5 (0.57) CYP2C9FFAR4CYP1A2KCNA5LMNA
SCHEMBL12201332 0.83 MEN1 (0.51) FFAR4LMNAMAPTSMN1; SMN2KMT2A
SCHEMBL7409071 0.83 LMNA (0.71) LMNAMAPTKMT2AMETAP2HTT
SCHEMBL5955298 0.82 FFAR4 (0.71) FFAR4LMNAMAPTSMN1; SMN2KMT2A
SCHEMBL12201251 0.82 LMNA (0.65) CYP2C9CYP1A2KCNA5LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1385820-B1 ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF SANOFI AVENTIS DEUTSCHLAND (DE) 2011-10-12 EP disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE KCNH1, KCNH2, KCNJ2 CYP2C9 1109/4885FFAR4 3044/4885CYP1A2 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.